RMB, keep in mind, they have not sold a nickel's worth in most of the markets they are approved in yet. I assume this is because it's just too expensive to launch in a small market. So those revenues would be extrapolated into the $500M number in a buyout. So I am not saying that AMARIN has to necessarily achieve $500M, but Vascepa will. But much of it may be in the hands of a new owner, who already has existing infrastructure in all of those countries.
This is why I think Sarissa's goal is to sell sooner than later. It is just economically difficult to run a one-drug pharma company, especially when you don't have a huge market pulling in big numbers (ie. U.S.).
Market Data 
Markets 
AI
